Singapore, Feb 10, 2012: In compliance with ASX Continuing Disclosure Rules, Genetic Technologies has executed a Settlement and License Agreement with Eurofins STA Laboratories of Longmont, Colorado, USA. Under the agreement, Eurofins STA is granted non-exclusive rights to a number of GTG patents relating to its non-coding DNA technology. As with other similar agreements, the precise commercial terms of the agreement are covered by formal confidentiality provisions and cannot be disclosed.

Eurofins STA was a counter-party to the third formal patent assertion suit filed by Genetic Technologies against ten companies in the US District Court for the District of Colorado and is now the third counter-party in this case to settle with Genetic Technologies.

Discussions with other parties both internal and external to the formal assertion program are ongoing and progressing.